Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept

NCT01875991 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01875991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01875991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
June 5, 2013
Completion date
March 4, 2014
Enrollment
217 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, rheumatoid arthritis